amgen

  1. T

    Amgen Highlights Data To Be Presented At American Society For Bone And Mineral Resear

    Amgen (NASDAQ: AMGN) announced that it will present data from several Prolia® (denosumab) studies, including eight year efficacy and safety data from a Phase 2 extension study in women with postmenopausal osteoporosis with low bone mineral density (BMD), at the 2011 American Society for Bone and...
  2. T

    Chrissie Fletcher, Director And Head Of International Biostatistics At Amgen, Discuss

    Chrissie Fletcher joined Pharma IQ to talk about Health Technology Assessment. In this comprehensive podcast, she discussed how she sees health economists and statisticians interacting going forwards, why there is so much emphasis on reporting for reimbursement and whether she expects pharma...
  3. T

    Amgen Director Shares Strategies To Maximise Reimbursement Success

    Pharma IQ has conducted an interview with Chrissie Fletcher, Director and Head of International Biostatistics at Amgen, about Health Technology Assessment. Fletcher said: "The Health Technology Assessment dossier is really the single opportunity that people have to convince payers of the value...
  4. T

    Amgen Highlights Data To Be Presented At American Society Of Hematology Annual Meetin

    Amgen (Nasdaq: AMGN) announced that it will present data from several key Nplate® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with...
  5. T

    Fda Approves Amgen's Xgeva™ (Denosumab) For The Prevention Of Skeletal-Related Events

    Amgen Inc. (NASDAQ: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved XGEVA™ (denosumab), the first and only RANK Ligand inhibitor for the prevention of skeletal-related events (SREs) in patients with bone metastases from solid tumors. XGEVA was approved following a 6...
  6. T

    FDA Approves Amgen's Prolia(TM) (Denosumab) For Treatment Of Postmenopausal Women Wit

    Amgen Inc. (Nasdaq: AMGN) announced that the U.S. Food and Drug Administration (FDA) has approved Prolia™ (denosumab) for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or...
  7. J

    survey- how long does the amgen tour of california bike race last in one day?

    the one lance armstrong is racing in? i plan to go to the last race here in southern california on sunday. it starts at 12pm how long would it take them to get to the finish line? if i get to the finish line at 12:30pm is that a good time or a bad time. btw it doesnt say how long it takes from...
  8. J

    poll- what do you know about the amgen tour of california bike race?

    it's the tour de france of california
Back
Top